Macrophages and neutrophils orchestrate acute inflammation and host defense as well as the resolution phase and return to homeostasis. In this article, we review the contribution of macrophages to local lipid mediator (LM) levels and the regulation of macrophage LM profiles by polymorphonuclear neutrophils and neutrophil-derived microparticles. We carried out LM metabololipidomics, profiling distinct phagocytes: neutrophils (PMNs), apoptotic PMNs, and macrophages. Efferocytosis increased specialized proresolving mediator (SPM) biosynthesis, including resolvin D1 (RvD1), RvD2, and RvE2, which were further elevated by PMN microparticles. In studies using deuterium-labeled precursors (d 8 -arachidonic acid, d 5 -eicosapentaenoic acid, and d 5 -docosahexaenoic acid), apoptotic PMNs and microparticles contributed to SPM biosynthesis during efferocytosis. Assessment of macrophage LM profiles in M2 macrophages demonstrated higher SPM levels in this macrophage subset, including maresin 1 (MaR1), and lower amounts of leukotriene B 4 (LTB 4 ) and prostaglandins than in M1. Apoptotic PMN uptake by both macrophage subtypes led to modulation of their LM profiles. LTB 4 was downregulated in M2, whereas SPMs including lipoxin A 4 were increased. Conversely, uptake of apoptotic PMNs by M2 macrophages reduced (∼25%) overall LMs. MaR1 displays potent tissue-regenerative and antinociceptive actions in addition to its proresolving and anti-inflammatory actions. In addition, the MaR1 biosynthetic intermediate 13S,14S-epoxy-maresin is also bioactive, inhibiting LTB 4 biosynthesis and switching macrophage phenotypes from M1 to M2. Together, these results establish LM signature profiles of human phagocytes and related subpopulations. They demonstrate microparticle regulation of macrophage-specific endogenous LMs during defined stages of acute inflammation and their dynamic changes in human primary phagocytes.
INTRODUCTION
Inflammation is the organism's response to local injury in vascularized tissues programmed to traffic leukocytes and plasma delivery to an injured site or point of bacterial invasion (1) ; this protective response, when uncontrolled in humans, is associated with many widely occurring diseases. These include cardiovascular, metabolic, and the classic inflammatory diseases, e.g., arthritis and periodontal disease, along with cancers (reviewed in reference 2). Nonresolving inflammation is now widely acknowledged as a major driver in most of these diseases (for a review, see reference 3). The classical view of the resolution phase of the acute inflammatory response as understood and presented in pathology textbooks (1, 4) as well as in medical dictionaries (5) was that local inflammatory chemical messengers and cells were passively diluted at the site (dilution of chemotactic gradient), hence halting further leukocyte recruitment and resolving the exudate or battlefield of inflammation (6, 7) . The historical perspective on the origins and concepts in the medical community regarding the resolution of inflammation apparently trace back as early as 11th-century Europe, and interested readers can refer to a recent review (8) .
Regarding the origins that led pathologists to consider the resolution of inflammation as a passive process, the reader is directed to reference 9. In considering the outcomes of acute inflammation, pathologists con-sidered four major paths: (i) complete resolution, (ii) abscess formation, (iii) healing by connective tissue replacement (fibrosis), and (iv) progression of the tissue on to chronic inflammation. Specifically, in considering complete resolution, it was noted that in an ideal situation all inflammatory responses, once they have succeeded in neutralizing injurious stimuli, must come to a termination or end with the restoration of the site of acute inflammation and its return to normality. This process, termed resolution, is the usual outcome when the injury is limited or short-lived or when there has been little tissue destruction and the damaged parenchymal cells can regenerate (9) . Resolution thus involves "the neutralization or spontaneous decay of the local chemical mediators with the return of normal vascular permeability, cessation of leukocytic infiltration" (9) and cell death (largely by cellular apoptosis of neutrophils) and their removal, as well as the removal of edema, foreign agents, and necrotic debris from the inflammatory site. These events were held to take place primarily via phagocytic processes of phagocytes and the lymphatics (4, 9) . Thus, while the events leading to resolution were thought to be seemingly chaotic, the process is highly organized as observable via microscopy of histological tissue sections, leading pathologists to the original ideas regarding resolution as a passive and spontaneous process.
The study of chemical mediators initially focused on those signals, local-acting autacoids, that play critical roles in the initiation process. Local mediators such as histamine, complement split products (C5a and C3b), and chemokines serve as chemoattractants to bring neutrophils, which are the first responders in many instances, via diapedesis from postcapillary venules into tissues to combat injury and invading organisms. In this process of initiation of inflammation intended to neutralize foreign invaders, arachidonic acid (AA)-or n-6-derived mediators play a critical role. In this regard, prostaglandins are known to play pivotal roles in inflammation, and leukotrienes, in particular leukotriene B 4 (LTB 4 ), play a pivotal role as the key chemoattractants involved in the hierarchy of chemoattractants (10, 11) . The gradient of chemoattractants such as LTB 4 is critical in enabling neutrophils to smell the chemical signal per se and move directedly along the gradient. Prostaglandin E 2 (PGE 2 ) plays a critical role in the hemodynamic changes and responses of endothelial cells, which permit neutrophils to migrate past them during diapedesis. All of these events are critical in the initiation process, and for the better part of the last century investigators focused their efforts on defining the mediators and mechanisms involved in initiating the acute inflammatory response, since this has led to therapeutic agents that can limit the dynamics and extent of the inflammatory response (12) (13) (14) .
It became evident that there are lipid mediators (LMs) that are also involved in endogenous anti-inflammation. In this regard, both PGE 2 and PGD 2 play special roles. There are multiple receptors for these eicosanoids, and their cell-specific signaling is dictated by specific G protein coupling, which is cell type specific. PGE 2 has anti-inflammatory actions such as stopping neutrophil migration, as does PGD 2 , but these mediators have a distinction in that they can induce the apparatus responsible for lipoxin production (15) . The distinction between anti-inflammation and resolution is defined below, but at this juncture it is important to point out that anti-inflammation and resolution are distinct processes. Proresolving processes are active events stimulating the uptake of, for example, apoptotic neutrophils and/or bacteria and their debris, while anti-inflammation is generally an inhibitory process, stopping leukocytic infiltration, for example. The distinction between these processes is now clear. One is an agonist, namely a proresolving mediator, while anti-inflammation can be initiated by a pharmacologic inhibitor or antagonist (16, 17) .
Results from this laboratory demonstrated that resolution of self-limited inflammatory exudates is a biochemically active process that involves the local and temporal biosynthesis of a new genus of specialized proresolving mediators (SPMs) with their novel functions mapped employing resolution indices (7, (18) (19) (20) . SPMs encompass several families of structurally and chemically distinct mediators. These chemical mediator families include lipoxins biosynthesized from AA; E-series resolvins from eicosapentaenoic acid (EPA); and docosahexaenoic acid (DHA)-derived D-series resolvins, protectins, and maresins. Each potent bioactive member of these families shares a defining action in resolving local inflammation. By definition, they each limit further polymorphonuclear neutrophil (PMN) recruitment to the site of injury and/or microbial invasion and enhance macrophage uptake of cellular debris and apoptotic PMNs to bring about tissue homeostasis (2, 21) . The placement of these mediators within the resolution of inflammation as well as the state-of-the art definitions are reviewed elsewhere (16, 21) .
The process of macrophage clearance is a critical process conserved throughout evolution. Elie Metchnikoff first described it in the late 19th century in starfish larvae. Since then, the role of this process has been extensively studied in mammalian systems, where it is appreciated to be critical in both the maintenance of homeostasis and the clearance of cellular debris, bacteria (22, 23) , and apoptotic cells, a process termed efferocytosis (24) . Along with these defining properties, specific members of the SPM genus carry out morespecialized tasks within programmed resolution (25) , and hence the scope of their individual actions is nonoverlapping and evoked via specific cell surface receptors that are G protein-coupled receptors (GPCRs) (2) . The role for specific SPMs in mediating the biological actions of SPMs is established using both mice overexpressing these receptors that give enhanced host protective actions as well as mice lacking the receptors that demonstrate excessive inflammation and loss of response to their specific SPM agonist(s). For example, in mice overexpressing the human lipoxin receptor (ALX), which also mediates the biological actions of resolvin D1 (RvD1), we found a reduction in the amplitude of the inflammatory response, accelerated resolution, and enhanced responses to lipoxin A 4 (LXA 4 ) (26) and RvD1 (27) . Similar results were also observed with transgenic mice overexpressing the receptor for RvE1, ChemR23/ ERV (28) , whereas in mice lacking the murine homolog of the ALX receptor there is excessive inflammation and decreased responses to these proresolving mediators (27, 29, 30) . For a detailed recent review, the reader is directed to reference 31.
From the recent literature, it is clear that specific LMs interact with GPCRs that can evoke cell type-specific responses. The specific responses of a given cell type could be mediated by different intracellular signals, such as cyclic AMP in the case of RvD2 (32) or other intracellular signals such as phosphorylation and receptor cross-desensitization (33) . Recent studies have also shown that proresolving actions of GPCRs, as in the case of ALX receptor, can differentially signal if they are in the heterodimer versus homodimer state (34) . These recent studies from Perretti and colleagues clearly demonstrate that heterodimer receptors with ALX and LXA 4 as the ligand can differentially signal. Further research is needed along these lines to decode each of the SPM receptors and their target cell type and tissue responses and intracellular signal transduction.
A systems approach led to the identification of novel bioactive structures coined resolvins and protectins in murine inflammatory exudates and isolated human cells based on liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based LM lipidomics and tandem assessment of their functions in anti-inflammation and proresolution (18, 35) . The complete stereochem-istry and total organic synthesis of several key resolvins, protectins, as well as their aspirin-triggered forms have been established (recently reviewed in references 21 and 36). These include RvD1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA), RvD2 (7S,16R,17Strihydroxy-4Z,8E,10Z,12E,14E,19Z-DHA), 17R-HDHA (17R-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-DHA), neuroprotectin D1 (NPD1) (10R,17S-dihydroxy-4Z,7Z, 11E,13E,15Z,19Z-DHA), RvE1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA), and most recently maresin 1 (MaR1) (7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-DHA) (37) . In addition to confirming the original structural assignments and potent anti-inflammatory and proresolving actions of resolvins, lipoxins, and maresins in vivo (36) , new studies from others demonstrate their potent actions in experimental colitis (38) , arthritis (39), arthritic pain (40) , ocular diseases (41) , and resolving obesity (42) and diabetes (43) . Importantly, synthetic SPMs permitted their identification in other biological sources, including, for example, human inflammatory responses (44, 45) , human serum (46) , fish (47) and other marine organisms (48) , and the invertebrate phyla (37) . These mediators also counterregulate the production of proinflammatory signals including LMs (e.g., leukotrienes and prostaglandins) and cytokines (e.g., tumor necrosis factor α and interleukin-6 [IL-6]) (21) and upregulate levels of host protective and anti-inflammatory mediators including proteins such as annexin A1 (reviewed in reference 49), gases including endogenous heme oxygenase-1-derived carbon monoxide (50) as well as endogenous hydrogen sulfide (51) , and cytokines including transforming growth factor β and IL-10 (reviewed in reference 52). For a detailed review of the role of cytokines in regulating steps during the resolution of inflammation, readers are directed to reference 52.
The discovery of potent bioactive resolvins and protectins in resolving exudates indicated that multiple cell types are involved in their biosynthesis, given the dynamic process ongoing within evolving inflammatory exudates (7, 18) . With authenticated SPMs and proinflammatory LMs, we can now carry out targeted LM metabololipidomics via profiling with monitoring >50 individual mediators and pathway markers from these autacoid pathways in initiation and resolution of inflammation (53) .
Microparticles in human synovium can influence the course of inflammation (54) . Microparticles are small, membrane-bound vesicles first identified by Peter Wolf in 1967, and were thought to be by-products of platelet activation carrying no significant biological activity (55) .
It is now appreciated that microparticles are produced by a large number of cells including leukocytes, muscle cells, and endothelial cells (54) . These microstructures are now appreciated to carry distinct functions in both the initiation and resolution of acute inflammation (reviewed in reference 56). Microparticles can act as vehicles carrying a wide range of molecular cargo, including microRNAs that are implicated in the regulation of hematopoiesis (57) as well as in protection during ischemia/reperfusion-mediated kidney injury (58) . The proinflammatory cytokine IL-1β is also carried by microparticles, and its loading into these microvesicles is thought to be one of the mechanisms by which this cytokine, which does not possess a secretion motif, is released from cells (59) . Morphogens, such as Sonic hedgehog, are also part of the cargo carried by subsets of these microparticles, whereby microparticles enriched in this morphogen were found to promote angiogenesis and thus may play a role in tumor growth (60) . Microparticles also express receptors that are incorporated from the parent cell plasma membrane during formation. These receptors may be functionally transferred to recipient cells, thereby expanding the receptor repertoire of the recipient cell, providing either a nongenomic gain of function or being involved in the pathogenesis of a number of infectious diseases, including HIV infection. In this context, monocyte microparticles carrying the C-C chemokine receptor type 5 (CCR5), the principal coreceptor for macrophagetropic HIV-1, transfer this receptor to endothelial cells during monocyte transendothelial migration, making the endothelial cells susceptible to infection by HIV-1 (61) .
Recently, we found that leukocyte microparticles also display anti-inflammatory actions (62), carry precursors for the biosynthesis of proresolving mediators (63, 64) , and display potent proresolving and host protective actions (63, 65) . Since evolving self-limited inflammatory exudates produce functional microparticles that also signal to stimulate resolution of inflammation in mice (63), we systematically profiled LMs and SPMs produced by individual human cell types and microparticles involved in initiation and gauged their contributions to resolution of inflammatory responses. Employing a targeted LM metabololipidomic approach, we found that apoptotic PMNs possess a proresolving LM profile and their uptake stimulated SPM biosynthesis in macrophages, a process that is also regulated by PMN microparticles and transcellular biosynthesis (64) that can also impact aging (66) , pain (67), as well as vagus nerve control of resolution (68) .
APOPTOTIC PMN AND MICROPARTICLES STIMULATE MACROPHAGE SPM PRODUCTION
We assessed endogenous pro-and anti-inflammatory LM biosynthesis by human macrophages during uptake of apoptotic PMNs using targeted LC-MS/MS metabololipidomics emphasizing functional lipidomics. We identified mediators from both lipoxygenase and cyclooxygenase pathways, including RvD1, MaR1, PGE 2 , and PGF 2α, (Fig. 1A ). All were identified in accordance with published criteria (53) that included matching retention times, fragmentation patterns, and at least six characteristic and diagnostic ions for each as illustrated with results obtained for RvD1 LM quantification is achieved via multiple reaction monitoring (MRM) of signature ion pairs Q1 (parent ion) and Q3 (characteristic daughter ion) (Fig. 1C ). Macrophage efferocytosis of apoptotic PMNs increased SPM biosynthesis, primarily RvD1 (18 ± 10 versus 127 ± 14 pg/2.5 × 10 5 cells), RvD2 (28 ± 8 versus 124 ± 12 pg/2.5 × 10 5 cells), and LXB 4 (19 ± 2 versus 44 ± 6 pg/2.5 × 10 5 cells). This was accompanied by increases in prostanoids including PGE 2 (7 ± 1 versus 44 ± 12 pg/2.5 × 10 5 cells; Fig. 1C ) . Having found that microparticles stimulate efferocytosis, we assessed their actions on SPM biosynthesis during apoptotic PMN uptake. Microparticles stimulated macrophage biosynthesis of RvD2 (219 ± 44 versus 124 ± 12 pg/2.5 × 10 5 cells), LXB 4 (84 ± 15 versus 44 ± 6 pg/2.5 × 10 5 cells), and RvE2 (478 ± 57 versus 199 ± 26 pg/2.5 × 10 5 cells) to a greater extent than apoptotic PMNs, while reducing PGF 2α (259 ± 29 versus 459 ± 54 pg/2.5 × 10 5 cells) and thromboxane B 2 (TXB 2 ) (328 ± 21 versus 456 ± 62 pg/2.5 × 10 5 cells) (Fig. 1C) .
Temporal SPM biosynthesis contributes to regulating the onset of resolution programs (2) . Therefore, we assessed the cumulative levels for each LM family identified (64) . During human macrophage efferocytosis there was an increase in DHA-( Fig. 2A ) and AA-derived SPM (Fig. 2B ) biosynthesis, along with an augmentation in prostanoid production ( Fig. 2C ). Microparticles further enhanced apoptotic PMN-stimulated SPM biosynthesis ( Fig. 2A and B ) while reducing prostanoid production ( Fig. 2C ). To rule out the possibility that microparticles carried mediators in addition to their known ability to carry SPM precursors (63), we profiled the microparticles. Microparticles did not carry mature SPMs. ASMscience.org/MicrobiolSpectrum 5
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Hence, we profiled the amounts of LMs associated with apoptotic PMNs and microparticles in the absence of efferocytosis. Although specific SPMs and LMs were demonstrable, their values were baseline compared to levels produced via macrophages during efferocytosis (64). Whether PMN microparticles are able to stimulate macrophage LM biosynthesis was also investigated. Incubation of PMN microparticles with macrophages led to the biosynthesis of lipoxygenase-and cyclooxygenasederived LMs (64) . These included RvD5, protectin D1 (PD1), and PGE 2 in accordance with criteria (53) that included matching retention times and at least six diagnostic ions as illustrated for MaR1, PD1, RvE2, and RvE1. These results are the first to demonstrate each of these proresolving mediators in human macrophage incubations and their interrelationships.
In these experiments we observed, for example, that PMN microparticles led to an increase in MaR1 (13 ± 4 versus 21 ± 2 pg/2.5 × 10 5 macrophages), PD1 (7 ± 1 versus 28 ± 5 pg/2.5 × 10 5 macrophages), LXB 4 (78 ± 4 versus 248 ± 26 pg/2.5 × 10 5 macrophages), and RvE1 (14 ± 8 versus 72 ± 9 pg/2.5 × 10 5 macrophages) production. Also, we found that PMN microparticles stimulated macrophage prostanoids, in particular PGE 2 (18 ± 2 versus 40 ± 6 pg/2.5 × 10 5 macrophages) and TXB 2 (28 ± 7 versus 63 ± 10 pg/2.5 × 10 5 macrophages). Cumulative LM metabololipidomics for each LM family identified demonstrated that PMN microparticles stimulated biosynthesis of DHA-( Fig. 2A) , AA- (Fig. 2B) , and EPA-derived SPMs along with prostanoids ( Fig.  2C ). Of interest, incubation of macrophages with G protein inhibitors (pertussis toxin and cholera toxin) reduced SPM biosynthesis without altering prostanoid levels. Together, these results demonstrate that microparticles selectively stimulate macrophage SPM production in a GPCR-dependent manner (64, 66) .
MICROPARTICLES STIMULATE EFFEROCYTOSIS OF APOPTOTIC PMNS
Since PMN microparticles exert anti-inflammatory and proresolving actions in vivo (63), we assessed their ability to regulate macrophage uptake of apoptotic cells (efferocytosis) (17) . Fluorescently labeled PMN microparticles were obtained from activated PMNs and incubated with macrophages prior to addition of fluorescent apoptotic PMNs that dose dependently increased macrophage-associated fluorescence (Fig. 2D) . These results indicate that microparticles regulate efferocytosis of apoptotic cells and stimulate the biosynthesis of SPMs ( Fig. 2E ).
APOPTOTIC PMNS POSSESS A PRORESOLVING LM PROFILE
Because apoptotic PMNs stimulate macrophage SPMs during efferocytosis (64), we investigated mediator profiles of apoptotic PMNs in comparison to zymosan-stimulated PMNs. Using targeted LM metabololipidomics, we identified a profile signature of LMs that included RvD1, LXB 4 , PGD 2 , and PGE 2 . Identification was achieved (vide supra) as illustrated for RvE2, PD1 (also known as NPD1/ PD1 when produced in neural systems [19] ), RvD2, and LTB 4 . MRM LM quantification of signature ion pairs demonstrated that AA-derived LMs represents >∼85% of the apoptotic PMN AA, EPA, and DHA identified LM metabolome. In these cells, the DHA-derived mediators represented ∼6% while EPA-derived mediators amounted to ∼11% of the targeted LMs. On the other hand, with zymosan-stimulated PMNs, AA-derived LMs constituted ∼81% of the targeted AA, EPA, and DHA LM metabolomes.
Comparison of endogenous LMs identified in apoptotic versus zymosan-activated PMNs revealed that RvD1 (42 ± 12 versus 5 ± 2 pg/5 × 10 6 cells) and LXB 4 (142 ± 37 versus 14 ± 7 pg/5 × 10 6 cells) biosynthesis was reduced in zymosan-stimulated cells. Similarly, there was a downregulation in a number of cyclooxygenasederived LMs in zymosan-stimulated PMNs, including PGD 2 (123 ± 29 versus 82 ± 15 pg/5 × 10 6 cells), PGE 2 (390 ± 75 versus 82 ± 16 pg/5 × 10 6 cells), and PGF 2α (127 ± 40 versus 52 ± 18 pg/5 × 10 6 cells). Production of the chemoattractant LTB 4 (including its 20-OH P450 metabolite) was elevated in zymosan-stimulated cells as opposed to apoptotic PMNs. For intact PMNs without exposure to agonists, the levels for these mediators were close to or below limits. In order to gauge the effector functions endowed upon PMNs by their individual LM profiles, we assessed the cumulative LM amounts for the distinct LM families identified using LM metabololipidomics. We found that apoptotic PMNs produced significantly higher SPMs and prostanoids than zymosan or intact PMNs. Assessment of AA-, EPA-, and DHAderived monohydroxy products did not reveal significant differences between apoptotic, zymosan-stimulated, or intact PMNs (64) .
To appreciate the sequence of events involved in LM production during human PMN apoptosis, we also identified LMs present at distinct stages of PMN progression to apoptosis determined by annexin V staining. Since, during inflammation, edema formation supplies the inflammatory response with extracellular substrate (69), we determined the time course of LM biosynthesis by apoptotic cells in the presence of extracellular substrate. MRM quantification of identified LMs demonstrated a significant increase in SPM biosynthesis by apoptotic cells, including D-and E-series resolvins, that reached maximum within 30 min (64) . Prostanoids were also elevated, while LTB 4 (including its 20-OH metabolite) occurred during the initial phase and subsequently declined, both in the presence and absence of substrate. Although we were not able to rule out that a small proportion of potentially nonapoptotic PMNs that might have been present could have contributed to LM profiles in incubations with apoptotic PMNs, it is more than likely that at the 18-h interval LM profiles reflect the capacity of apoptotic PMNs to biosynthesize specific LMs.
APOPTOTIC PMNS AND MICROPARTICLES, A NIDUS FOR MACROPHAGE SPM BIOSYNTHESIS
The potential contribution of transcellular biosynthesis was assessed, in particular for SPMs, during macrophage efferocytosis (64) . For this purpose we utilized deuterium-labeled (d) precursors, which allowed for the identification of mediators from substrate/precursors derived from either apoptotic PMNs or microparticles. LMs derived from d-substrate had a higher mass-tocharge ratio (m/z) than those biosynthesized from en-dogenous substrate. Specifically, LMs produced from d 8 -AA were 8 atomic mass units (amu) and those from d 5 -EPA and d 5 -DHA were 5 amu greater than LMs biosynthesized from endogenous precursors. We first fortified microparticles and apoptotic PMNs with d-labeled precursors and assessed levels of d-labeled LMs, essential fatty acids (AA, EPA, and DHA), and biosynthetic precursors (including 18-hydroxy-eicosapentaenoic acid (HEPE), 15-HEPE, 15-hydroxy-eicosatetraenoic acid (HETE), 17-HDHA, and 14-HDHA). We identified LM precursors including d 5 -DHA, d 5 -17-HDHA, and d 8 -AA along with a select number of mediators, including d 5 -RvD5 and d 5 -RvE2, in accordance with published criteria (53) . MRM quantitation of the identified LMs demonstrated that the levels of these d-labeled mediators within microparticles and apoptotic PMNs were near limits of detection (<5 pg LM/6 × 10 5 microparticles and <1 pg LM/1 × 10 6 PMNs). We also identified d-labeled biosynthetic precursors that included 16 ± 3 pg d 5 -17-HDHA/5 × 10 5 microparticles and 18 ± 1 pg d 5 -17-HDHA/7.5 × 10 5 apoptotic PMNs and d-labeled essential fatty acids that included 423 ± 35 pg d 5 -DHA/5 × 10 5 microparticles and 459 ± 133 pg d 5 -DHA/7.5 × 10 5 apoptotic PMNs. These results suggested that while there was a significant enrichment of d-labeled precursors in both microparticles and apoptotic PMNs, only a relatively minor proportion was further converted to bioactive LMs in the absence of macrophages.
In these studies, we added either d-labeled microparticles or d-labeled apoptotic PMNs to macrophages, assessing LM transcellular biosynthesis during macrophage efferocytosis (64) . Apoptotic PMN uptake by macrophages led to the biosynthesis of d 5 -RvD2 and d 5 -RvD5 from the D-series resolvins, d 5 -PD1 from the protectins, d 8 -LXB 4 from the lipoxins, and d 5 -RvE2 from the E-series resolvins, while d 8 -PGD 2 and d 8 -PGF 2α were the only prostanoids identified, and d 5 -RvD5, d 5 -RvE2, and d 8 -LXB 4 where the atomic mass of the parent molecules was increased by either 5 or 8 amu. MRM quantification of d-LMs biosynthesized during macrophage efferocytosis suggested that microparticles acted as a nexus for d 5 -RvD2, d 5 -RvD5, d 8 -LXA 4 , d 8 -PGE 2 , and d 8 -PGF 2α production. d 5 -MaR1 and d 8 -LXB 4 biosynthesis were primarily sustained by precursors derived from within apoptotic PMNs. d 5 -PD1 and d 5 -RvE2 biosynthesis were equally reliant on precursors from apoptotic cells and microparticles. These results demonstrate that transcellular biosynthesis contributes to LM production during macrophage efferocytosis in which both apoptotic PMNs and microparticles contribute to and sustain a nidus for LM biosynthesis.
HUMAN MACROPHAGE SUBTYPES YIELD DISTINCT LM AND SPM PROFILES
Following LM metabolomics of M1 and M2 macrophages that were prepared from human peripheral blood monocytes, we identified 35 distinct LMs, which included RvD1, PD1, MaR1, LXA 5 , LXB 5 , PGD 2 , and PGE 2 . These mediators were identified using their diagnostic fragmentation patterns, matching a minimum of six characteristic fragments, as shown for RvD2, PD1, RvE2, and LXA 5 . Using LM metabololipidomics with M1 macrophages, we found that AA-derived LMs amounted to ∼48% of LMs identified. On the other hand, LM metabololipidomics of M2 macrophages demonstrated that SPMs represented ∼50% of the identified AA, EPA, and DHA metabolome, consisting of D-series resolvins, protectins, and maresins (∼11%); lipoxins (∼15%); and E-series resolvins and lipoxins (∼24%).
Using MRM, we compared the endogenous biosynthesis of individual LMs between the two macrophage subtypes. In these experiments, we found that biosynthesis of distinct SPMs was elevated in M2 in comparison to M1 macrophages; these included RvD5 (196 ± 26 versus 43 ± 5 pg/2.5 × 10 5 cells), MaR1 (299 ± 8 versus 45 ± 8 pg/2.5 × 10 5 cells), PD1 (3,442 ± 206 versus 1,339 ± 206 pg/2.5 × 10 5 cells), LXA 4 (977 ± 173 versus 675 ± 167 pg/2.5 × 10 5 cells), LXB 4 (11,750 ± 724 versus 7,560 ± 659 pg/2.5 × 10 5 cells), LXB 5 (4,370 ± 397 versus 2,551 ± 859 pg/2.5 × 10 5 cells), and RvE2 (20,680 ± 4,910 versus 10,910 ± 4,232 pg/2.5 × 10 5 cells). Conversely, production of cyclooxygenase-derived LMs was elevated in M1 macrophages; these included PGE 2 (2,285 ± 435 versus 1,573 ± 490 pg/2.5 × 10 5 cells), PGF 2α (11,325 ± 428 versus 2,108 ± 256 pg/2.5 × 10 5 cells), TXB 2 (550 ± 135 versus 222 ± 73 pg/2.5 × 10 5 cells), and the EPA-derived prostanoids.
Because different human macrophage subtypes possess distinct LM profiles, we compared the cumulative amounts of different LM families identified in M1 and M2 macrophages in order to assess effector functions that these endow for the individual macrophage subtypes. SPM biosynthesis was higher in M2 compared to M1 macrophages, while production of prostanoids and leukotrienes LTB 4 and LTB 5 was elevated in M1 macrophages compared to M2 (Fig. 3) . Assessment of LM biosynthesis following apoptotic cell efferocytosis demonstrated that apoptotic PMN uptake gave SPMs in M1 macrophages while reducing prostanoids and leukotrienes. Apoptotic PMNs with M2 macrophages reduced overall LM production, including SPMs. These 
MAR1 IS PRORESOLVING AND TISSUE REGENERATIVE
Self-resolving inflammatory exudates and LM metabolomics recently uncovered a new family of potent antiinflammatory and proresolving mediators biosynthesized by macrophages, coined maresins (71) . It was essential to establish the stereochemistry of this pathway. We determined that MaR1 produced by human macrophages from endogenous DHA matched synthetic 7R,14Sdihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid. The MaR1 alcohol groups and Z/E geometry of conjugated double bonds were matched using isomers prepared by total organic synthesis. MaR1's potent defining actions were confirmed with synthetic MaR1, i.e., limiting neutrophil (PMN) infiltration in murine peritonitis in the ng per mouse dose range as well as enhancing human macrophage uptake of apoptotic PMNs. At 1 nM, MaR1 was slightly more potent than RvD1 in stimulating human macrophage efferocytosis, an action not shared by LTB 4 . MaR1 also accelerated surgical regeneration in planaria, increasing the rate of head reappearance (37) . Upon injury of planaria, MaR1 was biosynthesized from deuterium-labeled (d 5 )-DHA that was blocked with lipoxygenase inhibitor. Planaria are simple organisms FIGURE 4 The macrophage-derived proresolving mediator MaR1 stimulates tissue regeneration. (A to C) Anterior portions of brown planaria were surgically removed, planaria were exposed to vehicle or MaR1, and regeneration was assessed 4 days after surgery using fluorescently conjugated Erythrina cristagalli lectin to visualize secretory cells. (D) After surgery, planaria were kept in water-containing vehicle (Veh) or the indicated concentrations of MaR1. We direct interested readers to reference 37 for detailed experimental conditions. Results are mean ± SEM (n = 5 planaria/group). *P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle alone. capable of rapid regeneration, the process wherein mammalian tissue macrophages play distinct roles. Hence, we questioned whether MaR1 demonstrated properties in tissue regeneration. To this end, planaria were grown and their anterior portions were surgically removed and exposed to proresolving mediators (Fig. 4) . Planaria are increasingly recognized as a useful model system for tissue regeneration (72) . Factors are known to be involved in planaria tissue regeneration (72) . However, they remained to be identified. MaR1 and RvE1 at 100 nM each enhanced the rate of tissue regeneration, with the appearance of the anterior portion, i.e., head regeneration, evident as early as 3 days postsurgery ( Fig. 4) . We examined MaR1 dose dependency (Fig. 4 ). MaR1 at doses as low as 1, 10, and 100 nM enhanced tissue regeneration in the anterior head, which was statistically significant by days 3 and 4. By days 6 and 7, the actions were less prominent. MaR1-enhanced tissue regeneration was concentration dependent ( Fig. 4) (37) .
MaR1 also possesses potent antinociceptive actions, dose-dependently inhibiting TRPV1 currents in neurons, blocking capsaicin (100 nM)-induced inward currents (IC 50 = 0.49 ± 0.02 ng/ml), and reducing both inflammatory and chemotherapy-induced neuropathic pain in mice. These results demonstrate the potent actions of MaR1 in regulating inflammation resolution and tissue regeneration and resolving pain (8, 37, 67) . These findings suggest that chemical signals are shared in resolutive cellular trafficking important in tissue regeneration. Moreover, immunoresolvents of the innate immune response (8) , such as MaR1, offer new opportunities for assessing macrophages and their local DHA metabolome in the return to tissue homeostasis.
THE MARESIN BIOSYNTHETIC PATHWAY
In the biosynthesis of maresins, the 14-lipoxygenation of DHA by human macrophage 12-lipoxygenase (12-LOX) gave 14-hydro(peroxy)-docosahexaenoic acid (14-HpDHA) as well as several dihydroxy-docosahexaenoic acids, implicating an epoxide intermediate formation by this enzyme. Using a stereocontrolled synthesis, enantiomerically pure 13S,14S-epoxy-docosa-4Z,7Z,9E,11E, 16Z,19Z-hexaenoic acid (13S,14S-epoxy-DHA) was prepared and its stereochemistry was confirmed by nuclear magnetic resonance spectroscopy. When this 13S, 14S-epoxide was incubated with human macrophages, it was converted to MaR1. The synthetic 13S,14S-epoxide inhibited LTB 4 formation by human LTA 4 hydrolase by ∼40% (P < 0.05), to a similar extent as LTA 4 (∼50%; P < 0.05), but was not converted to MaR1 by this enzyme. 13S,14S-Epoxy-DHA also reduced (∼60%; P < 0.05) AA conversion by human 12-LOX. Incubation of 13S,14S-epoxy-DHA with M1 macrophages led to a change in macrophage phenotype toward an M2 profile (73) . Macrophage phenotype was determined using flow cytometry in which M1 macrophages expressed higher CD80 and CD54 while M2 macrophages displayed higher CD163 and CD206 levels. Incubation of M1 macrophages with either 13S,14S-epoxy-DHA (10 nM) or MaR1 (10 nM) led to significant reductions in CD54 and CD80 expression and a concomitant upregulation of CD163 and CD206 (Fig. 5 ). For comparison, this regulation was also found with RvD1 (10 nM). We also investigated the conversion of 13S,14S-epoxy-DHA to MaR1 by different human macrophage subtypes. Incubation of 13S,14S-epoxy-DHA (2 μM) with M2 macrophages gave higher MaR1 levels than when the 13S, 14S-epoxy-DHA was incubated with M1 macrophages as determined by LM metabololipidomics.
These results establish the biosynthesis of the 13S, 14S-epoxide, its absolute stereochemistry, its precursor role in MaR1 biosynthesis, and its own intrinsic bioactivity (73) . Given its actions and role in MaR1 biosynthesis, this epoxide is now termed 13,14-epoxy-maresin (13,14-eMaR) and exhibits new mechanisms in resolution of inflammation in its ability to inhibit proinflammatory mediator production by LTA 4 hydrolase and to block arachidonate conversion by human 12-LOX rather than merely terminating phagocyte involvement. Thus, these findings identify novel regulatory actions of DHA-derived mediators within the eicosanoid cascade FIGURE 6 Maresin biosynthesis and actions. DHA is converted by human 12-LOX through a lipoxygenase reaction involving the abstraction of hydrogen and the antarafacial addition of molecular oxygen at carbon 14 to produce 14S-HpDHA, which is also converted to the 13,14-epoxide by the same enzyme (88), denoted 13S,14S-epoxide-maresin, which is further converted to the bioactive MaR1, which promotes resolution, reduces pain signaling, and promotes tissue regeneration. See the text for further details, as well as references 37, 71, and 73. The epoxide 13S,14S-epoxy-maresin is also bioactive and inhibits LTA 4 hydrolase, limiting the production of LTB 4 as well as the conversion of AA to 12S-HpETE. These actions of the maresin epoxide indicate that activation of the pathway leads to downregulation of proinflammatory mediators during resolution. and in macrophage phenotypes (Fig. 6 ) that can play a role in vascular integrity (74) as well as in aging (66), tissue regeneration (37, 71) , pain (67) , and host defense mechanisms (75) , all critical life processes that are regulated by neutrophils and ultimately by specific macrophage subtypes in which resolution phase signals such as the proresolving mediators (resolvins, protectins, and maresins) actively turn on homeostatic mechanisms. Therefore, SPMs emerge as potent regulators of macrophage responses of interest during the resolution phase of acute inflammatory responses. Since the means and methodologies to identify these mediators have only recently become widely available, a number of aspects of their biology in humans have only just started to be explored, such as the production of these mediators in human tissues (76) (77) (78) . In addition, a number of questions remain to be addressed, such as when and where these mediators are produced in human tissues in health and disease and the relevance of resolution processes that may fail, giving rise to human disease. For those interested in the future directions and questions to be addressed, we direct readers to reference 21.
LOOKING AHEAD
In the near future, given the ability now to profile both proinflammatory and anti-inflammatory proresolving mediators such as the SPMs in human tissues (78) , and in other human organs (79) (80) (81) including human placenta (82), plasma (78, 81) , and milk (83) , it is possible that LM and SPM signature profiles will be very useful in both precision and personalized medicine. In this regard, the profile of SPMs can serve as a barometer of diagnostic value for ranking the nutritional status of individuals and whether or not they can be timely or slow resolvers of a local acute inflammatory challenge (44) . For example, a randomized controlled trial in human chronic kidney disease showed that n-3 fatty acid supplementation increases SPMs, which may help improve inflammation in this disease (84) . Most importantly, we will be able to establish whether specific SPMs (resolvins, protectins, or maresins) act locally to evoke their biological responses or if they have a distal site of action. In this regard, we recently identified resolvins, protectins, and maresins in human milk, which suggests that they could have a local site of action but also could be active in the newborn (85) . Most importantly, such methods of profiling initiators of inflammation and proresolving mediators in human tissues will help to assess the nutritional status of an individual. For example, what are the optimal levels of omega-3 essential fatty acids such as EPA and DHA as well as n-6 AA needed at a local tissue site to ensure timely neutralization of invading foreign injury as well as timely resolution and homeostasis? There are clearly age-and gender-related components in the resolution of inflammation, as we have found that the ability to resolve acute inflammatory responses in a timely fashion diminishes with age in mouse models (66) . Perhaps it will be possible to personalize our nutrition to impact resolution in both an age-and gender-dependent manner to improve health and reduce disease burden by enhancing local resolution of inflammation that could diminish chronic inflammation and the impact of chronic inflammatory diseases on organs throughout the body. In addition to tailoring designer medical foods to personalized nutrition, it is also possible to use each of the proresolving mediators as templates for analogs that can be used as therapeutics to stimulate resolution of inflammation as a new approach to resolution pharmacology (86) . This has already been extended to ongoing human clinical trials in ocular indications (http://www.auventx.com /auven/products/rx10045php) and for periodontal disease (87) .
Given that resolution of inflammation is a fundamental process in all human tissues and that phagocytes and specifically macrophages play a central role in orchestrating this response, as well as tissue repair and regeneration, immunoresolvents (such as resolvins, protectins and maresins) may provide a novel therapeutic approach for diseases characterized by uncontrolled inflammation and failed resolution.
